Trials / Completed
CompletedNCT02184884
Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 195 (actual)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength, maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A study reported that the TEG® can be used as routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay, we could find out the perioperative clopidogrel responsiveness of the patients with ACS undergoing OPCAB. The purpose of this study is to determine whether the rate of the major adverse cardiac events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in the patients with high degree of clopidogrel resistance, who are scheduled to undergo the OPCAB due to ACS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MACE after OPCAB | |
| DEVICE | without MACE after OPCAB |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2020-03-30
- Completion
- 2020-03-30
- First posted
- 2014-07-09
- Last updated
- 2020-05-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02184884. Inclusion in this directory is not an endorsement.